29936-92-3

Upstream product

• 120-47-8 Ethyl 4-hydroxybenzoate 
• 105-36-2 ethyl bromoacetate 
• 99-96-7 4-hydroxy-benzoic acid 

Downstream Products

• 25389-23-5 ethyl 4-(2-hydroxyethoxy)benzoate 
• 56703-36-7 4-(2-Iodoethoxy)-benzoic acid ethyl ester 
• 41386-38-3 4-(2-Bromo-ethoxy)-benzoic acid ethyl ester 
• 1027062-64-1 4-(2-Methanesulfonyloxy-ethoxy)-benzoic acid ethyl ester 
• 170799-65-2 ethyl 4-<2-(2-cyano-3-methoxy-2-cyclopentenyl)ethoxy>benzoate 
• 149325-67-7 4-<2-(2,4-diamino-6,7-dihydro-5H-cyclopentapyrimidin-5-yl)ethoxy>benzoic acid 
• 170799-60-7 ethyl 4-<2-(2,4-diamino-6,7-dihydro-5H-cyclopentapyrimidin-5-yl)ethoxy>benzoate 
• 170799-52-7 diethyl N-<4-<2-(2,4-diamino-6,7-dihydro-5H-cyclopentapyrimidin-5-yl)ethoxy>benzoyl>-L-glutamate 
• 102196-18-9 2-(4-(hydroxymethyl)phenoxy)ethanol 
• 30893-58-4 4-(ethoxycarbonyl)phenoxyacetic acid 

Relevant academic research and scientific papers

A synthesis method of [...] derivatives (by machine translation)

The invention discloses a [...] derivative 4 - (2 - bromine ethoxy group) [...] synthetic method, to the hydroxy benzoic acid as the starting material, through esterification, condensation, reduction, brominated to obtain the target compound, the compound is an important medical intermediates. (by machine translation)

Synthetic method of 4-chlorotoluene compound

The invention discloses a synthetic method of a 4-chlorotoluene compound 4-(2-chloroethoxy) benzyl chloride. According to the synthetic method, p-hydroxybenzoic acid is taken as an initial raw material, and the target compound is obtained via esterification, condensation, reduction, and chlorination. The target compound is an important pharmaceutical intermediate.

Condensed pyrimidine derivative

A novel pyrimidine derivative having an excellent antitumor activity, which is represented by the following general formula (I) or a pharmacologically acceptable salt thereof: STR1 wherein R1 represents a hydroxyl or amino group; R2 represents a phenylene, pyridinediyl, thiendiyl, furandiyl or thiazoldiyl group, --CO2 R5 and --CO2 R6 may be the same or different from each other and each represents a carboxyl group or a carboxylic acid ester, the part STR2 A represents an oxygen atom, a group represented by the formula: STR3 (wherein R3 and R4 may be the same or different from each other and each represents a hydrogen or halogen atom or a hydrocarbon group which may be substituted, or alternatively R3 and R4 may be united to form an alkylidene group which may be substituted) or a group represented by the formula: STR4 (wherein R70 represents a hydrogen atom or a hydrocarbon group), and n is an integer of 1 to 3, provided that the compound in which R1 represents oxygen, and hydrogen is attached to nitrogen at 3-position is included in the above shown definition, a process for preparation the same, and an antitumor drug containing the same.

Novel 6-5 fused ring heterocycle antifolates with potent antitumor activity: Bridge modifications and heterocyclic benzoyl isosters of 2,4-diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine antifolate

Structural modifications of an extremely potent inhibitor of dihydrofolate reductase (DHFR) activity and tumor cell growth, N-[4-[3-(2,4-diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidin-5-yl)propyl ]benzoyl]-L-glutamic acid (1), have led to the synthesis of